Michael Byrnes
Director of Finance/CFO chez EFFECTOR THERAPEUTICS, INC.
Fortune : 24 895 $ au 31/03/2024
Profil
Michael Byrnes is an Independent Director at CERo Therapeutics Holdings, Inc. since 2024.
He is also the Chief Financial Officer & Secretary at eFFECTOR Therapeutics, Inc. since 2020.
Previously, he worked as a Finance Director at NeurogesX, Inc. from 2007 to 2010, Controller at Maxygen, Inc. from 2010 to 2014, and Manager-Finance & Accounting at Lipid Sciences, Inc. from 2002 to 2007.
In addition, he served as the Senior Vice President-Finance at Principia Biopharma, Inc. in 2020, Chief Financial Officer at Alkahest, Inc. from 2018 to 2020, and Chief Financial Officer at OCERA Therapeutics LLC from 2014 to 2017.
Mr. Byrnes holds an MBA from California State University-East Bay and an undergraduate degree from Santa Clara University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 29/02/2024 | 1 730 ( 0,05% ) | 24 895 $ | 31/03/2024 | |
-.--% | 05/04/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Michael Byrnes
| Sociétés | Poste | Début |
|---|---|---|
| EFFECTOR THERAPEUTICS, INC. | Director of Finance/CFO | 01/12/2020 |
Anciens postes connus de Michael Byrnes
| Sociétés | Poste | Fin |
|---|---|---|
| PRINCIPIA BIOPHARMA INC. | Director of Finance/CFO | 01/09/2020 |
Alkahest, Inc.
 Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Director of Finance/CFO | 01/01/2020 |
| OCERA THERAPEUTICS INC | Director of Finance/CFO | 01/12/2017 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Comptroller/Controller/Auditor | 01/12/2014 |
| NEUROGESX, INC | Director of Finance/CFO | 01/03/2010 |
Formation de Michael Byrnes
| California State University-East Bay | Masters Business Admin |
| Santa Clara University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| EFFECTOR THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Lipid Sciences, Inc.
 Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | Commercial Services |
Principia Biopharma, Inc.
 Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
Alkahest, Inc.
Alkahest, Inc. BiotechnologyHealth Technology Alkahest, Inc. operates as biopharmaceutical company. It focuses on developing of treatments for neurodegenerative and age-related diseases. The company is headquartered in San Carlos, CA. | Health Technology |
Ocera Therapeutics, Inc.
 Ocera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ocera Therapeutics, Inc. manufactures pharmaceuticals products. The company was founded in 2004 and is headquartered in Hazelwood, MO. | Health Technology |
NeurogesX, Inc.
 NeurogesX, Inc. Pharmaceuticals: MajorHealth Technology NeurogesX, Inc. developed and commercialized novel pain management therapies. The company was founded by Wendye R. Robbins on May 28, 1998 and was headquartered in San Mateo, CA. | Health Technology |
